multi-payload
Callio Therapeutics Debuts with $187M to Develop Next-Generation Multi-Payload ADCs for Cancer
Multi-payload ADCs, antibody-drug conjugates, oncology, HER2-targeted therapy, dual-payload technology, cancer treatment, biotechnology startup